(0.19%) 5 141.00 points
(0.18%) 38 510 points
(0.27%) 17 893 points
(-0.93%) $83.07
(1.66%) $1.955
(-0.31%) $2 340.00
(-0.24%) $27.47
(0.25%) $924.40
(-0.14%) $0.933
(-0.03%) $11.02
(-0.18%) $0.799
(1.00%) $92.80
2.35% $ 3.49
Live Chart Being Loaded With Signals
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis...
Stats | |
---|---|
Volumen de hoy | 1 419.00 |
Volumen promedio | 6 052.00 |
Capitalización de mercado | 173.41M |
EPS | $0 ( 2024-04-11 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.63 |
ATR14 | $0 (0.00%) |
Genfit SA Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Genfit SA Finanzas
Annual | 2023 |
Ingresos: | $28.57M |
Beneficio Bruto: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2023 |
Ingresos: | $28.57M |
Beneficio Bruto: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2022 |
Ingresos: | $20.20M |
Beneficio Bruto: | $19.95M (98.77 %) |
EPS: | $-0.480 |
FY | 2021 |
Ingresos: | $80.07M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $1.510 |
Financial Reports:
No articles found.
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico